A phase 2 randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of AL002 in participants with Early Alzheimer’s disease (NCT04592874)
INVOKE-2
This trial is No longer recruiting
Registration number NCT04592874
Program & service
This trial is being run with the Brain service, and as part of the Neurology program.
Trial phase
Phase 2
Trial participation type
This trial has been designed for the Clinical Research of a Drug.
Principal investigator
Professor Terence O'Brien
More information
To find out more about this clinical trial, please review full details on the ANZCTR website.
View on ANZCTRIf you would like further details or have any questions about this clinical trial, we encourage you to get in touch with us and a member of our team will be happy to provide you with more information.